Know your risk. Track your changes. Own your health.
Earlier detection. Better outcomes.
Zedsen's novel sensing technology, combined with advanced AI/ML, provides non-invasive, radiation-free, affordable and portable assessment of breast density and cancer risk.
Actionable Results
Early accurate screening with quantitative results powered by advanced, bespoke algorithms, operable by all health staff.
De-centralising Healthcare
Our non-invasive, affordable and portable design makes it uniquely suitable as a diagnostic tool in GP and community clinic settings.
Early Diagnosis
Breast cancer is the most common cancer amongst women globally — with 1 in 8 diagnosed during their lifetime. There is a 98% chance of recovery if detected and treated early. Current screening methods fail women with dense breast tissue, disproportionately affecting women of colour and younger women.
Zedsen has developed an AI-native, mobile and cost effective sensor technology, enabling quantified measurement of breast composition.
←→
2025
Non-invasive classification between benign and cancerous breast lesions via time-domain bioimpedance sensing: a first-in-human study.
San Antonio Breast Cancer Symposium (SABCS)
Poster · Accepted
2026
High negative predictive value from a handheld non-ionising breast scan: feasibility evidence for symptomatic triage.
UK Imaging and Oncology Congress (UKIO)
Conference Abstract · Accepted
2026
Breast malignancies exhibit a distinct bioelectric phenotype detectable by time-domain bioimpedance.
European Association for Cancer Research Annual Congress (EACR)
Conference Abstract · Accepted
2026
Machine learning classification of breast density from bioimpedance signals.
Intl. Conference on Informatics, Management and Technology in Healthcare (ICIMTH)
Short Communication · Accepted
2026
Breast density classification in the presence of uncertainty.
IEEE Engineering in Medicine and Biology Society (EMBC)
Conference Paper · Decision Pending